Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Gains from Investment Securities (2023 - 2025)

Historic Gains from Investment Securities for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q1 2025 value amounting to $442000.0.

  • Artiva Biotherapeutics' Gains from Investment Securities rose 152580.65% to $442000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $475000.0, marking a year-over-year increase of 56901.41%. This contributed to the annual value of $149000.0 for FY2024, which is 20719.42% up from last year.
  • Artiva Biotherapeutics' Gains from Investment Securities amounted to $442000.0 in Q1 2025, which was up 152580.65% from $33000.0 recorded in Q4 2024.
  • Artiva Biotherapeutics' 5-year Gains from Investment Securities high stood at $442000.0 for Q1 2025, and its period low was -$45000.0 during Q4 2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $33000.0 (2024), whereas its average is $73571.4.
  • As far as peak fluctuations go, Artiva Biotherapeutics' Gains from Investment Securities skyrocketed by 17333.33% in 2024, and later surged by 152580.65% in 2025.
  • Quarter analysis of 3 years shows Artiva Biotherapeutics' Gains from Investment Securities stood at -$45000.0 in 2023, then skyrocketed by 173.33% to $33000.0 in 2024, then surged by 1239.39% to $442000.0 in 2025.
  • Its Gains from Investment Securities was $442000.0 in Q1 2025, compared to $33000.0 in Q4 2024 and $38000.0 in Q3 2024.